← Back to Search

Neodyne Device for Scar Improvement in Breast Reconstruction

N/A
Recruiting
Led By Arash Momeni, MD
Research Sponsored by Stanford University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Age >18
Female Subjects who have undergone unilateral/bilateral microsurgical breast reconstruction with free abdominal flaps within approximately 1 week (4-8 days) prior to study participation
Must not have
Subjects diagnosed with scleroderma
Subjects with oozing, dehiscence, non-closed/healed incisions at time of first application
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing a special device called the Neodyne embrace to see if it can make scars look better after breast reconstruction surgery. It focuses on women who have had this surgery using tissue from their abdomen. The device works by reducing skin tension around the scar, which helps it heal more nicely.

Who is the study for?
This trial is for women over 18 who've had microsurgical breast reconstruction with abdominal flaps within the last week. They must have a similar scar appearance along the incision, be able to understand and consent to study requirements, and not currently smoke or have certain medical conditions like connective tissue diseases or significant recent weight loss.
What is being tested?
The trial is testing the Neodyne embrace device's effectiveness on improving the appearance of abdominal scars after breast reconstruction surgery. It's a randomized controlled trial (RCT), which means participants are randomly assigned to receive either the embrace device treatment or no treatment for comparison.
What are the potential side effects?
Potential side effects may include skin reactions related to sensitivity towards steri-strip tapes, medical tapes, or adhesives used in conjunction with the Neodyne embrace device.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am older than 18 years.
Select...
I had breast reconstruction with tissue from my abdomen about a week ago.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have been diagnosed with scleroderma.
Select...
My surgical wound is not fully healed and is leaking.
Select...
I have lost more than 100 lbs in the last 6 months before my surgery.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Scar Assessment

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Group I: Neodyne DeviceExperimental Treatment1 Intervention
After eligible patients have provided informed consent, the side of the abdomen to be treated with the Neodyne Device will be randomly selected by opening a sealed randomization envelope. The selected side will be treated with the Neodyne Device through the full study. The Neodyne Device will be applied to a portion of the abdominal incision by the health care provider at 1 week (4-8 days) after the procedure. The other portion of the abdominal incision (Arm Title: Control) will serve as the control and will be treated per the investigator's standard of care. Subjects will return to the Investigator's office for a total of 8 weeks for application and removal of the Neodyne Dressing.
Group II: ControlExperimental Treatment1 Intervention
See above

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for scars, such as the Neodyne embrace device, work by reducing mechanical tension across the incision, which helps prevent scar widening and hypertrophy. This is crucial for scar patients as it can significantly improve the cosmetic appearance of scars. Other treatments, like nonablative fractional laser therapy, promote collagen remodeling by heating the dermis, leading to collagen contraction and new collagen formation. These mechanisms are important because they address both the structural and aesthetic aspects of scar healing, providing patients with better overall outcomes.
Laser therapy for treating hypertrophic and keloid scars.

Find a Location

Who is running the clinical trial?

Stanford UniversityLead Sponsor
2,472 Previous Clinical Trials
17,501,718 Total Patients Enrolled
Arash Momeni, MDPrincipal InvestigatorStanford University
2 Previous Clinical Trials
112 Total Patients Enrolled

Media Library

Neodyne Device Clinical Trial Eligibility Overview. Trial Name: NCT05377723 — N/A
Scar Research Study Groups: Neodyne Device, Control
Scar Clinical Trial 2023: Neodyne Device Highlights & Side Effects. Trial Name: NCT05377723 — N/A
Neodyne Device 2023 Treatment Timeline for Medical Study. Trial Name: NCT05377723 — N/A
~31 spots leftby Oct 2025